RU2206611C2 - ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ - Google Patents

ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ Download PDF

Info

Publication number
RU2206611C2
RU2206611C2 RU94028712/13A RU94028712A RU2206611C2 RU 2206611 C2 RU2206611 C2 RU 2206611C2 RU 94028712/13 A RU94028712/13 A RU 94028712/13A RU 94028712 A RU94028712 A RU 94028712A RU 2206611 C2 RU2206611 C2 RU 2206611C2
Authority
RU
Russia
Prior art keywords
polypeptide
protease activity
dna fragment
nucleotide
plasmid vector
Prior art date
Application number
RU94028712/13A
Other languages
English (en)
Other versions
RU94028712A (ru
Inventor
Рой А. БЛЭК (US)
Рой А. БЛЭК
Паул Р. СМИТ (US)
Паул Р. СМИТ
Ширлей Р. КРОНХЕЙМ (US)
Ширлей Р. КРОНХЕЙМ
Original Assignee
Вертекс Фармасьютикалз Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вертекс Фармасьютикалз Инкорпорейтед filed Critical Вертекс Фармасьютикалз Инкорпорейтед
Publication of RU94028712A publication Critical patent/RU94028712A/ru
Application granted granted Critical
Publication of RU2206611C2 publication Critical patent/RU2206611C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8142—Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Изобретение относится к получению биологически активной IL-1β протеазы с помощью технологии рекомбинантных ДНК и может быть использовано в медицине. Изолирована последовательность ДНК, кодирующая полную аминокислотную последовательность (предшественник) IL-1β протеазы, в которой идентифицирована область, кодирующая "зрелую" форму фермента. В результате экспрессии названных последовательностей ДНК в культуре клеток млекопитающего синтезируется биологически активная IL-1β протеаза, обладающая способностью расщеплять неактивный предшественник IL-1β в положении между 116 и 117 аминокислотными остатками с образованием активного цитокина. 4 с.п.ф-лы, 2 табл., 7 ил.

Description

Текст описания в факсимильном виде. Тм

Claims (4)

1. Фрагмент ДНК, кодирующий полипептид, обладающий IL-1β протеазной активностью и имеющий полинуклеотидную последовательность от нуклеотида 1 до нуклеотида 1232, или от нуклеотида 374 до нуклеотида 1232 в SEQ ID NO:1, или подобную последовательность, определяемую вырожденностью генетического кода.
2. Плазмидный вектор для экспрессии IL-1β протеазной активности в клетках млекопитающего, содержащий в сайте клонирования фрагмент ДНК по п.1.
3. Способ получения полипептида, обладающего IL-1β протеазной активностью, включающий стадии: a) культивирования клеток млекопитающего, продуцирующих указанный полипептид, в условиях, подходящих для его биосинтеза; и б) выделения и очистки продукта, в котором клетки, продуцирующие указанный полипептид, трансформированы рекомбинантным экспрессирующим вектором, включающим фрагмент ДНК от нуклеотида 374 до нуклеотида 1232 в SEQ ID NO:1, или подобную последовательность, определяемую вырожденностью генетического кода.
4. Полипептид, обладающий IL-1β протеазной активностью, получаемый способом по п.3.
RU94028712/13A 1991-08-30 1991-09-12 ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ RU2206611C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75064491A 1991-08-30 1991-08-30
US750,644 1991-08-30

Publications (2)

Publication Number Publication Date
RU94028712A RU94028712A (ru) 1997-03-10
RU2206611C2 true RU2206611C2 (ru) 2003-06-20

Family

ID=25018683

Family Applications (2)

Application Number Title Priority Date Filing Date
RU94028712/13A RU2206611C2 (ru) 1991-08-30 1991-09-12 ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ
RU2002128757/13A RU2002128757A (ru) 1991-08-30 2002-10-25 Полипептид, протеаза, днк, вектор, способ получения протеазы, соединения, композиции, способ ингибирования активности, способ лечения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2002128757/13A RU2002128757A (ru) 1991-08-30 2002-10-25 Полипептид, протеаза, днк, вектор, способ получения протеазы, соединения, композиции, способ ингибирования активности, способ лечения

Country Status (22)

Country Link
US (2) US5756465A (ru)
EP (2) EP0600880B1 (ru)
JP (3) JP2759895B2 (ru)
KR (1) KR100226296B1 (ru)
AT (1) ATE257517T1 (ru)
AU (1) AU657701B2 (ru)
CA (1) CA2111100C (ru)
DE (1) DE69133354T2 (ru)
DK (1) DK0600880T3 (ru)
ES (1) ES2213138T3 (ru)
FI (1) FI935020A (ru)
HK (1) HK1014013A1 (ru)
HU (1) HU220098B (ru)
IE (1) IE913268A1 (ru)
IL (2) IL99598A (ru)
MX (1) MX9101346A (ru)
MY (1) MY131144A (ru)
NO (1) NO317129B1 (ru)
NZ (3) NZ335312A (ru)
PT (1) PT99118B (ru)
RU (2) RU2206611C2 (ru)
WO (1) WO1993005071A1 (ru)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US6995141B1 (en) 1990-04-04 2006-02-07 Vertex Pharmaceuticals Incorporated Interleukin 1β protease and interleukin 1β protease inhibitors
HU220098B (hu) * 1991-08-30 2001-10-28 Vertex Pharmaceuticals Incorporated Interleukin-1 béta proteáz enzim, és interleukin-1 béta proteáz inhibitorok
IL105741A0 (en) * 1992-05-22 1993-09-22 Genta Inc Pharmaceutical compositions for treating cellular hyperproliferation using interleukin-1 inhibitory compounds
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
DE69413167T2 (de) * 1993-06-04 1999-05-06 Vertex Pharma Peptid-Phosphinyloxymethyl-Ketonen als Inhibitoren von Interleukin-1 beta-konvertierenden Enzymen
EP0711174A4 (en) * 1993-06-24 1997-11-12 Gen Hospital Corp REGULATORY GENES OF PROGRAMMED CELL DEATH AND PROTEINS
US6087160A (en) * 1993-06-24 2000-07-11 The General Hospital Corporation Programmed cell death genes and proteins
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5955072A (en) * 1994-07-13 1999-09-21 Sankyo Company, Limited Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
CA2202549C (en) * 1994-10-14 2003-08-05 Tara Seshadri Transgenic nonhuman animal having functionally disrupted interleukin-1.beta. converting enzyme gene
CA2215211A1 (en) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5869315A (en) * 1995-12-18 1999-02-09 Basf Aktiengesellschaft Modified interleukin-1β converting enzyme with increased stability
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US6288037B1 (en) 1996-01-29 2001-09-11 Basf Aktiengesellschaft Substrates and inhibitors for cysteine protease ICH-1
US6416753B1 (en) 1996-03-15 2002-07-09 The General Hospital Corporation Method for modulating apoptosis
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6531467B2 (en) 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
KR100580333B1 (ko) * 1997-10-10 2006-05-16 시토비아 인크. 디펩티드 고사 억제제 및 그의 용도
WO1999046248A1 (en) 1998-03-09 1999-09-16 Vertex Pharmaceuticals Incorporated 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
CA2323439A1 (en) * 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
PT1064298E (pt) 1998-03-19 2009-01-02 Vertex Pharma Inibidores de caspasas
CN1346344A (zh) * 1999-03-16 2002-04-24 西托维亚公司 取代的2－氨基苯甲酰胺天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其应用
DE19915465A1 (de) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten
JP2002541237A (ja) * 1999-04-09 2002-12-03 サイトビア インコーポレイテッド カスパーゼインヒビターおよびその使用
AU770380B2 (en) * 1999-06-14 2004-02-19 Wisconsin Alumni Research Foundation Oligomers and polymers of cyclic imino carboxylic acids
US6495522B1 (en) 1999-08-27 2002-12-17 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AU2001249619B2 (en) 2000-03-29 2006-08-17 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
EP1923386A3 (en) 2000-03-29 2008-05-28 Vertex Pharmceuticals Incorporated Carbamate caspase inhibitors and uses thereof
WO2001087328A2 (en) * 2000-05-12 2001-11-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
EA006860B1 (ru) * 2002-01-29 2006-04-28 Уайт Композиции и способы модулирования гемиканалов коннексина
US7009053B2 (en) 2002-04-30 2006-03-07 Yungjin Pharmaceuticals Co., Ltd. Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
AU2004275821A1 (en) * 2003-09-25 2005-04-07 Dmi Biosciences Inc. Methods and products which utilize N-acyl-L-aspartic acid
CA2566362C (en) 2004-05-15 2013-09-10 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CN1980658A (zh) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
US7618801B2 (en) * 2007-10-30 2009-11-17 Danison US Inc. Streptomyces protease
WO2012061786A1 (en) 2010-11-05 2012-05-10 Brandeis University Ice cleaved alpha-synuclein a biomarker
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2124233B (en) * 1982-07-19 1985-09-18 Nat Res Dev Synthetic peptides and their preparation
US4636492A (en) * 1984-08-29 1987-01-13 E. I. Du Pont De Nemours And Company Inhibition of viral protease activity by peptide halomethyl ketones
US5104853A (en) * 1984-12-11 1992-04-14 California Biotechnology Inc. Alveolar surfactant proteins having cys to ser mutations
US4644055A (en) * 1984-12-17 1987-02-17 E. I. Du Pont De Nemours And Company Method for preparing specific inhibitors of virus-specified proteases
JPS63145300A (ja) * 1984-12-17 1988-06-17 イ−・アイ・デユポン・デ・ニモアス・アンド・カンパニ− ウイルスにより特定されているプロテア−ゼの特異的阻害剤を製造する方法
US5225354A (en) * 1986-08-22 1993-07-06 Molecular Diagnostics, Inc. Monoclonal antibodies specific for human glycoalbumin
WO1991000912A1 (en) * 1989-07-07 1991-01-24 Massachusetts Institute Of Technology Production and use of hybrid protease inhibitors
AU7775991A (en) * 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
US5298421A (en) * 1990-04-26 1994-03-29 Calgene, Inc. Plant medium-chain-preferring acyl-ACP thioesterases and related methods
EP0533350B1 (en) * 1991-08-16 1999-05-26 Merck & Co. Inc. DNA encoding precursor interleukin 1B converting enzyme
HU220098B (hu) * 1991-08-30 2001-10-28 Vertex Pharmaceuticals Incorporated Interleukin-1 béta proteáz enzim, és interleukin-1 béta proteáz inhibitorok

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
1. R.A. BLACK et. al., FEBS Letters, v. 247, № 2, 386-390, 1989. 2. R.A. BLACK et. al., J. Biol. Chem., v. 263, № 19, 9437-9442, 1988. 3. R.A. BLACK et. al., J. Biol. Chem., v. 264, № 10, 5323-5326, 1989. *

Also Published As

Publication number Publication date
WO1993005071A1 (en) 1993-03-18
US6136787A (en) 2000-10-24
IL99598A0 (en) 1992-08-18
EP0600880A4 (en) 1994-12-21
CA2111100C (en) 2004-11-02
IL99598A (en) 2005-06-19
HUT66057A (en) 1994-09-28
KR100226296B1 (ko) 1999-10-15
HU9303244D0 (en) 1994-03-28
JP2001192397A (ja) 2001-07-17
RU94028712A (ru) 1997-03-10
ES2213138T3 (es) 2004-08-16
HU220098B (hu) 2001-10-28
EP1378573A1 (en) 2004-01-07
IL166791A0 (en) 2006-01-15
ATE257517T1 (de) 2004-01-15
RU2002128757A (ru) 2004-07-27
PT99118A (pt) 1993-02-26
AU657701B2 (en) 1995-03-23
NO934335D0 (no) 1993-11-30
EP0600880A1 (en) 1994-06-15
JPH1028588A (ja) 1998-02-03
FI935020A (fi) 1993-12-03
NO934335L (no) 1993-11-30
CA2111100A1 (en) 1993-03-18
DE69133354D1 (de) 2004-02-12
HK1014013A1 (en) 1999-09-17
AU8537391A (en) 1993-04-05
FI935020A0 (fi) 1993-11-12
EP0600880B1 (en) 2004-01-07
JP3445572B2 (ja) 2003-09-08
DE69133354T2 (de) 2004-11-11
NZ248377A (en) 2000-01-28
US5756465A (en) 1998-05-26
DK0600880T3 (da) 2004-04-13
NZ335312A (en) 2005-08-26
NO317129B1 (no) 2004-08-23
NZ239895A (en) 1996-01-26
IE913268A1 (en) 1993-03-10
JPH08505280A (ja) 1996-06-11
PT99118B (pt) 1999-02-26
MX9101346A (es) 1993-02-01
JP2759895B2 (ja) 1998-05-28
MY131144A (en) 2007-07-31

Similar Documents

Publication Publication Date Title
RU2206611C2 (ru) ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ
KR880014110A (ko) 인체 프로아포지방단백질 a-i의 발현
CA2257839A1 (en) Gamma-heregulin
RU2004126135A (ru) Новый цитокин zalpha11-лиганд
CA2352492A1 (en) Nucleic acid molecules encoding alternansucrase
CA2495482A1 (en) Novel peptide-forming enzyme gene
US11655464B2 (en) Alkaline protease mutant, and gene, engineered strain, preparation method and application thereof
CA2461443A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
CA2188279A1 (en) Interleukin-15 receptors
CA2327266A1 (en) Pesticidal toxins and nucleotide sequences which encode these toxins
CA2208324A1 (en) Recombinant proteinase from clostridium hystolyticum and the use thereof for isolating cells and cell groups
CA2266421A1 (en) Genes coding for a protein having glycoside transfer activity
NZ334568A (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
KR970001541A (ko) 엔도글리코세라미다아제 액티베이터를 코딩하는 유전자
US4935351A (en) Process for preparing oligopeptide
KR930702528A (ko) 스트렙토마이세스 리비단으로부터 분리하고 정제한 단백질 가수분해 효소 x를 암호화하는 dna 시퀸스
Wang et al. Cloning and expression of L-asparaginase gene in Escherichia coli
CA2384122A1 (en) Cyclic depsipeptide synthetase and gene thereof, and mass production system for cyclic depsipeptide
US5275946A (en) Thrombolytic agents with modified kringle domains
CA2301902A1 (en) Novel extracellular serine protease
WO2002010384A1 (fr) Genes codant des proteines capables de regenerer la luciferine, adn recombine et methode de production de proteines capables de regenerer la luciferine
JPH01211490A (ja) ヒト神経成長因子遺伝子セグメント
WO2002099092A8 (en) Production of recombinant human lysosomal alpha-mannosidase
JP2938352B2 (ja) 組換え人マトリライシンの製造方法
Kawauchi et al. Preparation and characterization of human rheumatoid arthritic synovial fluid phospholipase A2 produced by recombinant baculovirus-infected insect cells

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20050913